Our Company

CORPORATE RESPONSIBILITY

Accepting Challenges to Improve the Health of Humanity

Stemming from the core values of Alnylam, our approach to corporate responsibility embodies our “Challenge Accepted” philosophy. Our corporate responsibility mission statement—“Accepting challenges to improve the health of humanity”—helps articulate how we approach our work each day. It describes our commitment to tackling unprecedented and complex challenges, taking courageous action, and using our business as a force for good.

Download our 2022 Corporate Responsibility Report to review details on Alnylam’s CR policies, practices, and commitments.

In all we do, we know we must shift health inequities, addressing the underlying social, environmental, cultural, and economic factors that affect human health – the “social determinants of health,” or SDOH. We aim to build initiatives across Alnylam that advance this work throughout our 6 CR pillars: science, patients, employees, communities, planet, and governance.

Find our past Corporate Responsibility Reports here.

Corporate Responsibility Report

Go in-depth to learn more about our approach to corporate responsibility and specific actions we are taking as a company.

DOWNLOAD PDF

comprehensive goals met in MassBio’s Diversity, Equity and Inclusion (DE&I) public pledge

social enterprises supported through Acumen America’s Health Equity portfolio

of scope 1 and 2 Greenhouse
Gas (GHG) emissions third-party verified

Patients: We Strive to Improve Patients’ Lives and Enable Access to Potentially Life-Changing Treatments

At Alnylam, patients, their families and caregivers are at the forefront of everything we do. Alnylam teams throughout the world address issues related to disease education, diagnosis, treatment access, affordability, and equity. By actively listening to patients, their families, and caregivers, as well as healthcare providers and payers, we work to improve the patient journey every day.

Science: We Advocate for Science and Innovation to Address Critical Health and Social Issues

RNA interference (RNAi) has been a revolution in biology and has powered over 20 years of scientific pursuit that Alnylam moves forward each day. We believe that laboratory breakthroughs can be transformed into life-changing medicines for patients. We embrace our commitment to responsibly innovate, advance our science and pipeline, invest in R&D, collaborate across sectors, and advocate for science and the biopharmaceutical industry.

Employees: We Foster an Open, Diverse Culture Where Employees Feel Included, Supported, and Heard

Our business is powered by our employees, who are propelled by shared passion for innovation and desire to improve the lives of patients. We create opportunities for employees to expand their knowledge, grow their expertise, and incorporate diverse perspectives throughout their work.

Communities: We Actively Engage People in Tackling the World’s Most Pressing Community and Health Equity Challenges

Our patients, our employees and our business can only thrive when the communities surrounding us are resilient and sustainable. We prioritize addressing health inequities as a core focus of our community impact investments, and we actively seek to increase access to new medicines, improve the underlying social determinants of health that influence health outcomes, and help patients live healthier lives.

Alnylam Challengers – a Health Equity Community Impact Program
Alnylam Challengers – International Expansion
Engaging in Our Communities
STEM and RNAi Education

Planet: We Seek to Improve the Health and Sustainability of Our Planet

As a biopharmaceutical company focused on improving the health of humanity, we have an important role to play in creating a more sustainable planet. Our teams continuously address energy use, greenhouse gas emissions, water use, waste, and other areas. We have taken meaningful steps to collect baseline data across our most important areas of focus in environmental management, have established tracking and measurement tools, and are working to determine targets that drive our environmental performance forward.

Greenhouse Gas Emissions, Energy Use and Climate Change
Controlling Waste
Facility Projects and Upgrades
Sustainable Transportation
Water Management and Conservation

Governance: We Set High Standards for Our Employees and Partners

Our five-year business strategy, Alnylam P5x25, focuses on our transition to a top-five biotech by 2025. Investing in good governance is an essential business practice. We adhere to the highest level of ethical, compliance and legal standards and strive to apply a corporate responsibility (CR) lens toward business activities.